Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

Scientist says child's death reveals 'serious failures in risk assessment, transparency and institutional oversight' The death of a six-year-old girl after receiving an experimental gene-editing ...

Intellia Therapeutics is a clinical-stage leader focused on CRISPR-based gene editing to treat diseases at their genetic source. The company primarily advances therapies for hereditary angioedema (HAE ...

In one of the most incredible single-day moves this year, biotechnology stock uniQure (NASDAQ: QURE) surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its ...

2022 has been a terrible, horrible, no good, very bad year for biotech. The industry has suffered from the broader market environment and from some forces specific to biotech. Overall, investors have ...